Corrigendum to “Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy” [Biomaterials 89 (2016) 56–66] (Biomaterials (2016) 89 (56–66), (S0142961216001393), (10.1016/j.biomaterials.2016.02.025));Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy

Biomaterials

Volumn 89, Issue , 2016, Pages 56-66

  Ran, Li ^a   Tan, Xiaohua ^c   Li, Yanchun ^a   Zhang, Huafeng ^a   Ma, Ruihua ^b   Ji, Tiantian ^b   Dong, Wenqian ^a   Tong, Tong ^a   Liu, Yuying ^a   Chen, Degao ^a   Yin, Xiaonan ^a   Liang, Xiaoyu ^a   Tang, Ke ^a   Ma, Jingwei ^a   Zhang, Yi ^a   Cao, Xuetao ^a   Hu, Zhuowei ^e   Qin, Xiaofeng ^d   Huang, Bo ^a,b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SUZHOU INSTITUTE OF SYSTEMS MEDICINE   (China)

^e INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cancer therapy; Delivery system; Microparticles; Oncolytic adenovirus

Indexed keywords

ACTIVATION ANALYSIS; CELL MEMBRANES; CYTOLOGY; DISEASES; ONCOLOGY; TARGETED DRUG DELIVERY; TUMORS; VIRUSES;

CANCER THERAPY; CHEMOTHERAPEUTIC DRUGS; CLINICAL APPLICATION; DELIVERY SYSTEMS; MEMBRANE FRAGMENTS; MICRO-PARTICLES; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIROTHERAPY;

CONTROLLED DRUG DELIVERY;

ONCOLYTIC ADENOVIRUS; VIRUS RECEPTOR; DRUG CARRIER; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; EXOSOME; FEMALE; IN VIVO STUDY; INTERCELLULAR SPACE; KIDNEY FUNCTION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENE; VIRUS PARTICLE; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; MEMBRANE MICROPARTICLE; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL-DERIVED MICROPARTICLES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84959298897     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2020.120372     Document Type: Erratum

References (47)

1. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30(7):658-670.
2. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 2008, 7(6):529-540.
3. Chiocca E.A., Rabkin S.D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2014, 2(4):295-300.
4. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 2014, 14(8):559-567.
5. Coffin R.S. From virotherapy to oncolytic immunotherapy: where are we now?. Curr. Opin. Virol. 2015, 13:93-100.
6. Prestwich R.J., Harrington K.J., Pandha H.S., Vile R.G., Melcher A.A. Oncolytic viruses: a novel form of immunotherapy. Erringt. F. Expert Rev. Anticancer Ther. 2008, 8(10):1581-1588.
7. Heidi L. First cancer-fighting virus approved. Nature 2015, 526:622-623.
8. Mark S.F., Nicholas R.L., Wang Y.E. Systemic delivery of oncolytic viruses: hopes and hurdle. Adv. Virol. 2012, 2012:805629.
9. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. MolTher 2010, 18(2):243-250.
10. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 2006, 4(2):61-70.
11. Chauhan V.S., Furr S.R., Sterka D.G., Nelson D.A., Moerdyk-Schauwecker M., Marriott I., et al. Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology 2010, 400(2):187-196.
12. Wojton J., Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 2010, 21(2):127-134.
13. Sonabend A.M., Ulasov I.V., Tyler M.A., Rivera A.A., Mathis J.M., Lesniak M.S. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008, 26(3):831-841.
14. Pan P.Y., Chen H.M., Chen S.H. Myeloid-derived suppressor cells as a Trojan horse: a cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology 2013, 2(8):e25083.
15. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311(5768):1780-1784.
16. Munguia A., Ota T., Miest T., Russell S.J. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 2008, 15(10):797-806.
17. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. ClinOncol. 2010, 7(11):653-664.
18. Barnard A.S. Nanohazards: knowledge is our first defence. Nat. Mater. 2006, 5(4):245-248.
19. Bénédicte H., Martínez M.C., Kunzelmann C., Freyssinet J.M. Membrane microparticles: two sides of the coin. Physiology 2005, 20(1):22-27.
20. Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ. Res. 2010, 107(9):1047-1057.
21. Tang K., Liu J., Yang Z., Zhang B., Zhang H., Huang C., Ma J., Shen G.X., Ye D., Huang B. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochem. Biophys. Res. Commun. 2010, 400(3):432-436.
22. 2 to tumor cells. J. Immunol. 2013, 191(6):3453-3461.
23. Li D., Jia H., Zhang H., Lv M., Liu J., Zhang Y., Huang T., Huang B. TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b. Oncoimmunology 2012, 1(5):687-693.
24. Zhang Y., Zhang R., Zhang H., Liu J., Yang Z., Xu P., Cai W., Lu G., Cui M., Schwendener R.A., Shi H.Z., Xiong H. Huang B.Microparticles released by Listeria monocytogenes-infected macrophages are required for dendritic cell-elicited protective immunity. Cell Mol. Immunol. 2012, 9(6):489-496.
25. Tang K., Zhang Y., Zhang H., Xu P., Liu J., Ma J., et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat. Commun. 2012, 3:1282.
26. Zhang H., Tang K., Zhang Y., Ma R., Ma J., Li Y., et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling. Cancer Immunol. Res. 2015, 3(2):196-205.
27. Lichtenstein D.L., Wold W.S. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 2004, 11(12):819-829.
28. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol. Pharm. 2011, 8(1):12-28.
29. Jiang H., McCormick F., Lang F.F., Gomez-Manzano C., Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev. Anticancer Ther. 2006, 6(5):697-708.
30. Thaci B., Ulasov I.V., Wainwright D.A., Lesniak M.S. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2011, 2(3):113-121.
31. Zheng F.Q., Xu Y., Yang R.J., Wu B., Tan X.H., Zhang Q.W. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol. Sin. 2009, 30(5):617-627.
32. Liu J., Tan Y., Zhang H., Zhang Y., Xu P., Chen J., et al. Soft fibrin gels promote selection and growth of tumorigenic cells. Nat. Mater. 2012, 11(8):734-741.
33. Berk A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005, 24(52):7673-7685.
34. Atai N.A., Balaj L., Van Veen H., Breakefield X.O., Jarzyna P.A., Van Noorden C.J., et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J. Neuro Oncol. 2013, 115(3):343-351.
35. Halldén G. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol. Ther. 2003, 8(3):412-424.
36. Kruyt F.A., Curiel D.T. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 2002, 13(4):485-495.
37. Eriksson M., Guse K., Bauerschmitz G., Virkkunen P., Tarkkanen M., Tanner M., et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/Low cells. MolTher 2007, 15(12):2088-2093.
38. Hendrickx R., Stichling N., Koelen J., Kuryk L., Lipiec A., Greber U.F. Innate immunity to adenovirus. Hum. Gene Ther. 2014, 25(4):265-284.
39. Fitzpatrick Z., György B., Skog J., Maguire C.A. Extracellular vesicles as enhancers of virus vector-mediated gene delivery. Hum. Gene Ther. 2014, 25(9):785-786.
40. György B., Fitzpatrick Z., Crommentuijn M.H., Mu D., Maguire C.A. Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials 2014, 35(26):7598-7609.
41. Cao Y., Liu C., Gu Z., Zhang Y., Duan Y., Zhang Y., et al. Microparticles mediate human papillomavirus type 6 or 11 infection of human macrophages. Cell Mol. Immunol. 2015, 10.1038/cmi.2015.30.
42. Lee C.H., Kasala D., Na Y., Lee M.S., Kim S.W., Jeong J.H., Yun C.O. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials 2014, 35(21):5505-5516.
43. Mangel W.F., San Martín C. Structure, function and dynamics in adenovirus maturation. Viruses 2014, 6(11):4536-4570.
44. Mark P.D., Michael W. Coupling viruses to dynein and kinesin-1. EMBO J. 2011, 30(17):3527-3539.
45. Settembre C., Ballabio A. Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb. Perspect. Biol. 2014, 6(6):a016907.
46. Cantalupo G., Alifano P., Roberti V., Bruni C.B., Bucci C. Rab-interacting lysosomal protein (RILP): the Rab7 effector required for transport to lysosomes. EMBO J. 2001, 20(4):683-693.
47. Pu J., Schindler C., Jia R., Jarnik M., Backlund P., Bonifacino J.S. BORC, a multisubunit complex that regulates lysosome positioning. Dev. Cell. 2015, 33(2):176-188.